NATSAR PHARMACEUTICALS, INC.

CIK 0002134002 · Biotech · Private

RK-33, a small molecule inhibitor of DDX3 RNA helicase for triple-negative breast cancer treatment

Grants
$1.6M
1 award
Sector median: 1
Raised
$4.2M
1 Form D · May 2026
5 months since last filing
Contracts
—
No federal contracts on record
Patents
3
1 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Drug development of RK-33 for breast cancer treatment$1,634,811
Private capital raisedForm D · SEC$4,221,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1793PMed Holdings, LLC—$1.6M
1794Mekanistic Therapeutics, LLC——
1795SCIBAC INC.——
1796NATSAR PHARMACEUTICALS, INC.—$4.2M
1797vTv Therapeutics Holdings LLC——
1798Arbor Plastic Technologies, LLC—$910K
1799SUVALENT THERAPEUTICS INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • Venu RamanDirector · Executive Officer

Patents

USPTO · 1 granted of 3

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.